Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 9/20 | 0.70 |
| ▸ | ABL1 | P00519 | 9/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.49 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | CSF1R | P07333 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24696591 | 0.91 | KIT (0.72) | KITABL1FGFR1KDRCSF1R | |
| SCHEMBL24696421 | 0.89 | KIT (0.70) | KITABL1FGFR1KDRCSF1R | |
| SCHEMBL16250589 | 0.88 | KIT (0.67) | KITABL1FGFR1KDRCSF1R | |
| SCHEMBL14733993 | 0.87 | KIT (0.55) | KIT | |
| SCHEMBL24697059 | 0.84 | KIT (0.62) | KITABL1FGFR1KDRCSF1R | |
| SCHEMBL13130573 | 0.84 | KIT (0.62) | KITKDRCSF1R | |
| SCHEMBL19500723 | 0.83 | KIT (0.61) | KITABL1FGFR1KDR | |
| SCHEMBL16241753 | 0.83 | KIT (0.61) | KIT | |
| SCHEMBL4103102 | 0.83 | KIT (1.00) | KITABL1FGFR1KDRCSF1R | |
| SCHEMBL29856181 | 0.83 | KIT (1.00) | KITABL1FGFR1KDRCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493473-B2 | Processes for making ponatinib and intermediates thereof | APICORE US LLC (US) | 2016-11-15 | — | — | US | disclosed |
| US-20160108053-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | APICORE US LLC (US) | 2016-04-21 | — | — | US | disclosed |
| US-20140343282-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | APICORE, LLC (US) | 2014-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108053-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | ABL1, KRAS, ROS1 | KIT 533/4885ABL1 1/4885FGFR1 91/4885 |
| US-20140343282-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | ABL1, KRAS, ROS1 | KIT 533/4885ABL1 1/4885FGFR1 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.